Lotus Health Group Yönetim

Yönetim kriter kontrolleri 2/4

Lotus Health Group CEO'su Tao Li, Aug2022 tarihinde atandı, in görev süresi 2.25 yıldır. şirketin hisselerinin 0.017% doğrudan sahiptir ve bu hisselerin değeri CN¥ 1.37M dir. Yönetim ekibinin ve yönetim kurulunun ortalama görev süresi sırasıyla 3.8 yıl ve 4 yıldır.

Anahtar bilgiler

Tao Li

İcra Kurulu Başkanı

n/a

Toplam tazminat

CEO maaş yüzdesi	n/a
CEO görev süresi	2.3yrs
CEO sahipliği	0.02%
Yönetim ortalama görev süresi	3.8yrs
Yönetim Kurulu ortalama görev süresi	4yrs

Son yönetim güncellemeleri

Recent updates

These 4 Measures Indicate That Lotus Health Group (SHSE:600186) Is Using Debt Reasonably Well

Oct 14

Lotus Health Group Company (SHSE:600186) Stock Rockets 35% As Investors Are Less Pessimistic Than Expected

Oct 14

There's Reason For Concern Over Lotus Health Group Company's (SHSE:600186) Price

Aug 23

These 4 Measures Indicate That Lotus Health Group (SHSE:600186) Is Using Debt Reasonably Well

Jun 07

Lotus Health Group Company's (SHSE:600186) Business Is Trailing The Market But Its Shares Aren't

Apr 30

Here's Why Lotus Health Group (SHSE:600186) Has Caught The Eye Of Investors

Feb 27

CEO

Tao Li (52 yo)

2.3yrs

Görev süresi

CN¥155,900

Tazminat

Mr. Tao Li serves as Co-President of Lotus Health Group Company since August 10, 2022.

Liderlik Ekibi

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Tao Li	Co-President	2.3yrs	CN¥155.90k	0.017% CN¥ 1.4m
Xian Hui Luo	VP, Secretary & Director	4.5yrs	CN¥620.00k	0.014% CN¥ 1.1m
Jin Rui Wang	Assistant to the President	4.4yrs	CN¥480.00k	Veri yok
Haifeng Li	Vice President	4.8yrs	CN¥525.00k	0.014% CN¥ 1.1m
Jiasheng Cao	President & Director	no data	Veri yok	Veri yok
Teng Yu	VP & Supervisor	2.4yrs	Veri yok	Veri yok
Songfeng Yang	Assistant to the President	3.2yrs	Veri yok	0.011% CN¥ 911.6k

3.8yrs

Ortalama Görev Süresi

48yo

Ortalama Yaş

Deneyimli Yönetim: 600186 'un yönetim ekibi deneyimli olarak değerlendirilmektedir (ortalama görev süresi 3.8 yıldır).

Yönetim Kurulu Üyeleri

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Xian Hui Luo	VP, Secretary & Director	6.5yrs	CN¥620.00k	0.014% CN¥ 1.1m
Jiasheng Cao	President & Director	3.1yrs	Veri yok	Veri yok
Teng Yu	VP & Supervisor	4.8yrs	Veri yok	Veri yok
Maoxin Chen	Independent Director	4.8yrs	CN¥100.00k	Veri yok
He Jun Wang	Independent Director	4.8yrs	CN¥100.00k	Veri yok
De Zhou Zheng	Director	4.8yrs	CN¥620.00k	0.014% CN¥ 1.1m
Yijun Wang	Independent Director	2.3yrs	CN¥40.00k	Veri yok
Chen Yongjian	Director	4.8yrs	CN¥60.00k	Veri yok
Jian Guo	Director	3.1yrs	CN¥620.00k	0.014% CN¥ 1.1m
Tongsen Deng	Director	3.1yrs	Veri yok	Veri yok
Liu Jun	Chairman of the Supervisory Board	3.3yrs	Veri yok	Veri yok
William Li	Vice Chairman	2.3yrs	CN¥139.80k	Veri yok

4.0yrs

Ortalama Görev Süresi

51.5yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: 600186 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 4 yıldır).

Lotus Health Group Yönetim

Yönetim kriter kontrolleri 2/4

Anahtar bilgiler

Son yönetim güncellemeleri

Lotus Health Group Company, Annual General Meeting, May 21, 2024

Less than half of directors are independent

Less than half of directors are independent

Recent updates

Third quarter 2024 earnings released: EPS: CN¥0.036 (vs CN¥0.025 in 3Q 2023)

Lotus Health Group Company (SHSE:600186) announces an Equity Buyback for CNY 150 million worth of its shares.

These 4 Measures Indicate That Lotus Health Group (SHSE:600186) Is Using Debt Reasonably Well

Lotus Health Group Company (SHSE:600186) Stock Rockets 35% As Investors Are Less Pessimistic Than Expected

Lotus Health Group Company to Report Q3, 2024 Results on Oct 31, 2024

Investor sentiment improves as stock rises 25%

Now 22% overvalued

Second quarter 2024 earnings released

There's Reason For Concern Over Lotus Health Group Company's (SHSE:600186) Price

Now 21% overvalued

Lotus Health Group Company to Report First Half, 2024 Results on Aug 31, 2024

These 4 Measures Indicate That Lotus Health Group (SHSE:600186) Is Using Debt Reasonably Well

Lotus Health Group Company, Annual General Meeting, May 21, 2024

Lotus Health Group Company's (SHSE:600186) Business Is Trailing The Market But Its Shares Aren't

Full year 2023 earnings released: EPS: CN¥0.07 (vs CN¥0.03 in FY 2022)

Investor sentiment deteriorates as stock falls 16%

Full year 2023 earnings released: EPS: CN¥0.07 (vs CN¥0.03 in FY 2022)

Lotus Health Group Company to Report Q1, 2024 Results on Apr 30, 2024

New minor risk - Financial data availability

Here's Why Lotus Health Group (SHSE:600186) Has Caught The Eye Of Investors

Lotus Health Group Company to Report Fiscal Year 2023 Results on Apr 30, 2024

Lotus Health Group Company to Report Q3, 2023 Results on Oct 31, 2023

Less than half of directors are independent

Third quarter 2022 earnings released: EPS: CN¥0.009 (vs CN¥0.005 in 3Q 2021)

Second quarter 2022 earnings released: EPS: CN¥0.01 (vs CN¥0.013 in 2Q 2021)

Lotus Health Group Company (SHSE:600186) announces an Equity Buyback for CNY 100 million worth of its shares.

Lotus Health Group Company (SHSE:600186) announces an Equity Buyback for CNY 100 million worth of its shares.

First quarter 2022 earnings released: EPS: CN¥0.008 (vs CN¥0.008 in 1Q 2021)

Less than half of directors are independent

Second quarter 2021 earnings released: EPS CN¥0.013 (vs CN¥0.014 in 2Q 2020)

Lotus Health Group Company announced that it has received CNY 993.545246 million in funding from a group of investors

First quarter 2021 earnings released: EPS CN¥0.008 (vs CN¥0.009 in 1Q 2020)

Full year 2020 earnings released: EPS CN¥0.05 (vs CN¥0.05 in FY 2019)

Lotus Health Group Company to Report Fiscal Year 2020 Results on Mar 31, 2021

Full year 2020 earnings released: EPS CN¥0.05 (vs CN¥0.05 in FY 2019)

New 90-day high: CN¥3.07

New 90-day high: CN¥2.99

Third quarter earnings released

Lotus Health Group Company to Report Q3, 2020 Results on Oct 31, 2020

New 90-day high - CN¥2.90

CEO

Görev süresi

Tazminat

Liderlik Ekibi

Ortalama Görev Süresi

Ortalama Yaş

Yönetim Kurulu Üyeleri

Ortalama Görev Süresi

Ortalama Yaş